Immunophenotypic characterisation of untreated hMSCs
| CD markers . | Previous reports . | Present report . |
|---|---|---|
| CD10 | −* | − |
| CD31 | −*,† | − |
| CD34 | −*,†,‡ | − |
| CD38 | −*/low§ | − |
| CD44 | low*/+†,‡ | + |
| CD45 | −*,†,‡ | − |
| CD73 (SH3) | +† | + |
| CD90 | low*/+†,‡ | + |
| CD105 (SH2) | +† | + |
| CD117 | −*,§ | − |
| CD147 | +§ | + |
| αSMA | +¶,** | + |
| Calponin | +** | + |
| Caldesmon I | +** | + |
| Myo D | + | |
| Fibroblast Mab 1 B 10 | + | |
| Fibronectin Mab IST-3 | +‡ | + |
| Calretinin | − | |
| Parvalbumin | + | |
| Nestin | −‡/+† | +/− |
| NeuN | −‡ | − |
| Neurofilaments | −‡ | − |
| NSE | low‡ | − |
| Peripherin | − | |
| Synaptophysin | −‡ | − |
| Tau | −‡ | − |
| β-III-TUB | +†,‡ | + |
| GFAP | −‡/low† | − |
| S100 | −‡‡ | + |
| CNPase | − | |
| O4 | − |
| CD markers . | Previous reports . | Present report . |
|---|---|---|
| CD10 | −* | − |
| CD31 | −*,† | − |
| CD34 | −*,†,‡ | − |
| CD38 | −*/low§ | − |
| CD44 | low*/+†,‡ | + |
| CD45 | −*,†,‡ | − |
| CD73 (SH3) | +† | + |
| CD90 | low*/+†,‡ | + |
| CD105 (SH2) | +† | + |
| CD117 | −*,§ | − |
| CD147 | +§ | + |
| αSMA | +¶,** | + |
| Calponin | +** | + |
| Caldesmon I | +** | + |
| Myo D | + | |
| Fibroblast Mab 1 B 10 | + | |
| Fibronectin Mab IST-3 | +‡ | + |
| Calretinin | − | |
| Parvalbumin | + | |
| Nestin | −‡/+† | +/− |
| NeuN | −‡ | − |
| Neurofilaments | −‡ | − |
| NSE | low‡ | − |
| Peripherin | − | |
| Synaptophysin | −‡ | − |
| Tau | −‡ | − |
| β-III-TUB | +†,‡ | + |
| GFAP | −‡/low† | − |
| S100 | −‡‡ | + |
| CNPase | − | |
| O4 | − |
Constitutive expression of CD and lineage-specific markers by hMSCs cultured in standard growth medium as determined by immunostaining: +, most cells positive; low, few cells positive; −, negative. Our data are compared to those of previous studies: *Reyes et al., 2001; †Tondreau et al., 2004; ‡Woodbury et al., 2000; §Colter et al., 2001; ¶Kinner et al., 2002; **Galmiche et al., 1993; ††Lodie et al., 2002; ‡‡Deng et al., 2001.